University of Groningen

Mesenchymal Stromal Cells Are Retained in the Renal Cortex Independently of Their Metabolic State After Renal Intra-Arterial Infusion

Sierra-Parraga, Jesus M.; Munk, Anders; Andersen, Christine; Lohmann, Stine; Moers, Cyril; Baan, Carla C.; Ploeg, Rutger J.; Pool, Merel; Keller, Anna K.; Moller, Bjarne K.

Published in:
Stem cells and development

DOI:
[10.1089/scd.2019.0105](https://doi.org/10.1089/scd.2019.0105)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2019

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Sierra-Parraga, J. M., Munk, A., Andersen, C., Lohmann, S., Moers, C., Baan, C. C., Ploeg, R. J., Pool, M., Keller, A. K., Moller, B. K., Leuvenink, H., Hoogduijn, M. J., Jespersen, B., & Eijken, M. (2019). Mesenchymal Stromal Cells Are Retained in the Renal Cortex Independently of Their Metabolic State After Renal Intra-Arterial Infusion. *Stem cells and development*, 28(18), 1224-1235.
<https://doi.org/10.1089/scd.2019.0105>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Mesenchymal Stromal Cells Are Retained in the Porcine Renal Cortex Independently of Their Metabolic State After Renal Intra-Arterial Infusion

Jesus M. Sierra-Parraga,^{1,2} Anders Munk,³ Christine Andersen,³ Stine Lohmann,^{2,3} Cyril Moers,⁴ Carla C. Baan,¹ Rutger J. Ploeg,⁵ Merel Pool,⁴ Anna K. Keller,² Bjarne K. Møller,⁶ Henri Leuvenink,⁴ Martin J. Hoogduijn,¹ Bente Jespersen,³ and Marco Eijken^{3,6}

The regenerative capacities of mesenchymal stromal cells (MSCs) make them suitable for renal regenerative therapy. The most common delivery route of MSC is through intravenous infusion, which is associated with off-target distribution. Renal intra-arterial delivery offers a targeted therapy, but limited knowledge is available regarding the fate of MSCs delivered through this route. Therefore, we studied the efficiency and tissue distribution of MSCs after renal intra-arterial delivery to a porcine renal ischemia–reperfusion model. MSCs were isolated from adipose tissue of healthy male pigs, fluorescently labeled and infused into the renal artery of female pigs. Flow cytometry allowed MSC detection and quantification in tissue and blood. In addition, quantitative polymerase chain reaction was used to trace MSCs by their Y-chromosome. During infusion, a minor number of MSCs left the kidney through the renal vein, and no MSCs were identified in arterial blood. Ischemic and healthy renal tissues were analyzed 30 min and 8 h after infusion, and $1\text{--}4 \times 10^4$ MSCs per gram of tissue were detected, predominantly, in the renal cortex, with a viability $>70\%$. Confocal microscopy demonstrated mainly glomerular localization of MSCs, but they were also observed in the capillary network around tubuli. The infusion of heat-inactivated (HI) MSCs, which are metabolically inactive, through the renal artery showed that HI-MSCs were distributed in the kidney in a similar manner to regular MSCs, suggesting a passive retention mechanism. Long-term MSC survival was analyzed by Y-chromosome tracing, and demonstrated that a low percentage of the infused MSCs were present in the kidney 14 days after administration, while HI-MSCs were completely undetectable. In conclusion, renal intra-arterial MSC infusion limited off-target engraftment, leading to efficient MSC delivery to the kidney, most of them being cleared within 14 days. MSC retention was independent of the metabolic state of MSC, indicating a passive mechanism.

Keywords: mesenchymal stromal cells, renal intra-arterial, cell therapy, ischemia–reperfusion injury, porcine model

Introduction

MESENCHYMAL STROMAL CELLS (MSCs) have regenerative properties, which induce tissue regeneration in the injured kidney [1–3]. MSCs secrete a variety of cytokines and growth factors that stimulate endothelial cell proliferation, enhance angiogenesis, and reduce endothelium permeability

[4–7]. Moreover, MSCs are able to reduce inflammation through the secretion of immunoregulatory mediators and induce anti-inflammatory M2 macrophages [8–10].

Studies in rodents have shown that MSCs can improve renal function in a transplant model [11], and restore renal structure and function in an acute kidney injury model [12]. A swine renal artery stenosis model showed that MSCs are

¹Nephrology and Transplantation, Internal Medicine Department, University Medical Center Rotterdam, Erasmus MC, Rotterdam, the Netherlands.

²Department of Renal Medicine, Aarhus University Hospital, Aarhus, Denmark.

³Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark.

⁴Department of Surgery—Organ Donation and Transplantation, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

⁵Nuffield Department of Surgical Sciences and Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.

⁶Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.

able to reduce fibrosis and inflammation of the renal medulla [13]. Moreover, in a porcine transplant model MSC treatment improved glomerular and tubular functions and protected the kidney from fibrosis [14].

As a result, several clinical trials are now trying to translate this success into an effective MSC therapy [15]. In these trials, the safety and efficacy of intravenous (IV) MSC infusion were investigated as a treatment for different renal diseases and to improve the outcome of kidney transplantation [2]. In the aforementioned animal and human studies, IV infusion of MSC was proven to be an easy and safe administration route. However, IV delivery of MSC has been shown to have some limitations. IV-infused MSCs do not specifically target the injured organ [16], which could lead to unwanted off-site effects. It has been shown that IV infusion of MSCs leads to entrapment of MSCs in the lung microvasculature, from where they are rapidly cleared by the immune system [17–19].

Intra-arterial infusion is a promising option to deliver MSC specifically to injured organs, which increases MSC delivery efficiency compared with IV infusion [20,21]. This was demonstrated in a rat kidney transplantation model [22], and in kidney injury rat models of polycystic kidney disease [23] and glomerulonephritis [24].

Studies in an ovine model showed that administration of MSCs through the renal artery leads to their engraftment in glomerular and tubular capillaries [25]. In swine models, renal intra-arterial delivery of MSC has been shown to reduce inflammation and fibrosis and improved revascularization, restoring renal function [13,26]. In an acute kidney injury monkey model, MSCs infused through the renal artery were found in glomeruli and tubuli as well, and were able to restore renal function [27,28]. Moreover, a phase 1/2A human clinical trial has been carried out using renal intra-arterial infusion of autologous MSC without reporting any adverse effects [29].

Although renal intra-arterial MSC delivery is deemed feasible, the efficiency of MSC delivery is not known, which makes it difficult to study dose-dependent effects. In addition, the mechanisms behind the retention of MSC are unknown. To be able to better correlate renal intra-arterial-based MSC therapy with observed effects in clinical and preclinical studies, more detailed knowledge regarding MSC retention and localization is crucial. These key questions require answering to further understand the role of exogenously administered MSCs to the injured kidney and to explore the therapeutic use of MSCs for kidney repair.

In this study, renal intra-arterial MSC infusion was investigated in a porcine ischemia–reperfusion injury kidney model. This model allows us to study MSC delivery in human-sized kidneys, making it translatable to studies in humans. The goal of the study was to determine the efficiency and tissue distribution of MSC delivered through the renal artery as well as to elucidate the mechanism responsible for MSC retention and survival in the kidney after infusion.

Materials and Methods

Institutional regulations

Female pigs of Danish Landrace and Yorkshire cross-breed weighing 40 kg were used. Animal care and experiments followed guidelines by the European Union (directive 2010/63/EU) and local regulations. The Animal Experi-

ments Inspectorate approved the study (reference number 2013-15-2934-00925 and 2017-15-0201-01367).

Isolation and expansion of MSCs

Subcutaneous adipose tissue was collected from healthy 40–60 kg male Danish landrace pigs during surgery as a waste product. In total, 4 g fat was cut in small pieces and washed twice with 30 mL Dulbecco's phosphate buffered saline (DPBS; ThermoFisher, Manhattan, NY) by centrifugation at 850g for 5 min. Adipose tissue was dissociated in 10 mL RPMI-1640 medium (ThermoFisher) containing 150 U/mL collagenase type IV (ThermoFisher) in a GentleMACS Octo tissue dissociator (Miltenyi Biotec, Bergisch Gladbach, Germany) using protocol 37C-mr-ATDK-1. After dissociation, 10 mL culture medium was added, and cells were pelleted at 650g for 10 min. Pellet was resuspended in 10 mL culture medium, and filtered through a 70 µm cell strainer and seeded in culture flasks.

Cells were cultured at 37°C and 5% CO₂ until they reached 80%–90% confluency (~7 days). Culture medium was replaced twice a week, and MSCs were subcultured until passage 3 before use or cryostored in 50% serum, 10% dimethyl sulfoxide (DMSO) in liquid N₂. MSC culture medium consisted of minimum essential medium (Sigma-Aldrich) supplemented with 15% fetal bovine serum (FBS; Sigma-Aldrich), 50 U/mL penicillin +50 µg/mL streptomycin (ThermoFisher), and 2 mM L-glutamine (ThermoFisher).

MSC characterization

Morphology of MSCs was observed with an axiovert 40C microscope (Zeiss, Oberkochen, Germany) coupled to a Zeiss CanonSLR camera (Zeiss), and their fibroblastic appearance was confirmed (Fig. 1A). MSCs (p3) were characterized by the expression and absence of specific membrane markers. About 1×10^5 MSCs in 100 µL DPBS were incubated for 30 min with 1 µL antihuman CD29 (APC, catalog #17-0299-42; Biolegend), 1 µL CD44 (PE, catalog #17-0441-81; Biolegend), and 1 µL CD90 (BV421, catalog #561557; Biolegend), which are described to crossreact with swine species, and the absence of negative membrane markers was assessed with 5 µL anti-pig CD31 (FITC, catalog #MCA1746F; Bio-rad, Hercules, CA) and 5 µL anti-pig CD45 (FITC, catalog #MCA1222F; Bio-rad).

Next, the cells were analyzed by multiparameter flow cytometry using a Novocyte flow cytometer (ACEA Biosciences, Inc., San Diego, CA). All used MSC batches were >95% positive for CD29, CD44, CD90 and negative for CD31 and CD45 (Fig. 1B, C).

MSC size was measured directly after trypsinization. MSCs in suspension were transferred to a Burkert-Turk counting chamber (ThermoFisher), and pictures were made under 100× magnification and analyzed by ImageJ software (National Institutes of Health, Bethesda, MD) using plugins *ij_Geodesics* and *Cell Magic Wand*. The grid of the counting chamber was used as a size reference. For each cell, the maximum and minimum diameter was determined, and the average diameter was used to express cell diameter. For each MSC batch, cell diameter was determined of ~100 cells. The size of infused MSC ranged from 10 to 30 µm, and the median was 16–18 µm (Fig. 1D, E).

FIG. 1. Porcine MSC characterization. **(A)** Fibroblast-like morphology of MSC. **(B)** Flow cytometry plot of forward and side scatter of MSC. **(C)** Expression level of CD29, CD44, CD90, CD31, and CD45. **(D)** Micrograph of trypsinized MSC in a Burkert-Turk chamber. **(E)** Size distribution of infused MSC. MSC, mesenchymal stromal cell.

MSC labeling

MSCs were cultured until 90% confluency, trypsinized and labeled with Quantum dots (Qdot) 655 (ThermoFisher) using 1.5 μ L of the reagent per million MSC according to manufacturer's protocol immediately before the infusion. Fluorescence was measured before each infusion to establish the gating strategy to identify the MSC. For labeling with PKH-26 (Sigma), MSCs were cultured as mentioned, trypsinized, and labeling was performed following the manufacturer's protocol.

Heat inactivation of MSC

MSCs were heat inactivated (HI) as previously described [30]. MSCs were resuspended in DPBS ($1-2 \times 10^6$ /mL), and incubated at 50°C for 30 min and cooled down in ice for 5 min.

MSC administration

MSCs were pelleted by centrifugation (440g, 5 min) after trypsinization, heat inactivation, or labeling. MSCs were resuspended in DPBS and filtered over a 70 μ m cell strainer. Before administration, cells were counted and visually inspected under a microscope to confirm a single cell solution.

Tissue dissociation

In total, 0.5 g of renal tissue were cut into small pieces and dissociated using a GentleMACS Octo tissue dissociator (Miltenyi Biotec). Renal cortical tissue was dissociated in 2.5 mL RMPI 1640 (ThermoFisher) supplemented with 100 μ L enzyme D, 50 μ L enzyme R, and 12.5 μ L enzyme A of a multitissue dissociation kit 1 (Miltenyi Biotec) and run with protocol 37C_Multi_B. Renal medulla and lung tissue were dissociated in 2.5 mL buffer X supplemented with 25 μ L enzyme P, 25 μ L buffer Y, 50 μ L enzyme D, and 10 μ L enzyme A of a multitissue dissociation kit 2 (Miltenyi Biotec) and run with protocol 37C_Multi_E.

After dissociation, 8 mL RPMI-1640 were added, and the cell suspension was filtered through a 70 μ m cell strainer and centrifuged at 500g for 7 min. Pellets were resuspended in 3 mL culture medium, and analyzed immediately or cryopreserved in 50% FBS and 10% DMSO.

Plastic-adherent fraction of dissociated tissue

In total, 500 μ L cryopreserved dissociated tissue was thawed and seeded in a T75 culture flask (Nunc) with 10 mL MSC medium and incubated for 1 day at 37°C and 5% CO₂. Medium was fully removed after 24 h, and cells were incubated for an additional 4 h. Before trypsinization, cells were washed twice with PBS (without calcium and magnesium; ThermoFisher) and detached using 2 mL 0.05% trypsin-ethylenediaminetetraacetic acid (ThermoFisher). Cells were pelleted by centrifugation at 440g for 5 min, and measured by flow cytometry or stored at -20°C for subsequent DNA isolation.

Y-chromosome PCR

DNA was isolated from 10 mg of kidney tissue or from cell pellets from the adherent fraction using a NucleoSpin

Tissue DNA isolation kit (Macherey-Nagel, Düren, Germany) according to manufacturer's protocol. DNA was eluted in 100 μ L water, and Y-chromosome was detected by quantitative polymerase chain reaction using primers directed to the male specific repeat (MSR) located on the porcine Y-chromosome as previously done by Gruessner et al. [31].

Primers directed to porcine S100C gene were used as a pig DNA control. Primer sequences were as follows: MSR forward 5'-CCA TCG GCC ATT GTT TTC CTG TTC A-3', MSR reverse 5'-CCT CTG TGC CCA CCT GCT CTC TAC A-3', S100C forward 5'-ATG CTG GAA GGG ACG GTA ACA ACA-3', and S100C reverse 5'-GCT CAG CTG CTG TCT TTC ACT CGT-3'. qPCR mix consisted of 0.5 μ L DNA, 10 pmol of each primer, and 1 $\times$ KiCStart SybrGreen qPCR ReadyMix (Sigma-Aldrich Life Science) in a final volume of 25 μ L. Samples were run in duplicate on a ABI 7300 (Perkin Elmer). The thermocycling program included an initial step of 2 min at 50°C, subsequently 10 min at 95°C, followed by a 40 time repeat two-step cycle involving 95°C for 15 s and 60°C for 1 min.

Anesthetics and surgical procedure

The pigs were sedated with intramuscular injection of Stresnil® (2.2 mg/kg) to allow vein cannulation. Intravenous (IV) administration of Ketamine (6 mg/kg) and Midazolam (0.5 mg/kg) allowed intubation and ventilation, keeping CO₂ between 4.5 and 5.5 kPa. Anesthesia was maintained using IV-administered Fentanyl (15 μ g/kg/h) and Propofol (3.5 mg/kg/h) preceded by a bolus of 7.5 μ g/kg (Fentanyl) and 1.875 mg/kg (Propofol). A bolus of 1.5 L Ringer Acetate was administered within the first one and a half hour followed by a continuous infusion rate of 400 mL/h to maintain normal hydration and a mean arterial blood pressure $\geq$ 60 mmHg in all pigs. Introducers were inserted into the common carotid artery, external jugular vein, and femoral artery (Radifocus® Introducer II Terumo Europe, Leuven, Belgium). The experiments were conducted with or without renal ischemia.

MSC infusion during open surgery

The data presented in Figs. 2–4 were obtained from an open surgery procedure. After a midline incision and retroperitoneal exposure of the left kidney, a catheter was positioned in the aorta over a guidewire in the femoral sheath. The catheter was further inserted into the left renal artery where positioning was controlled by palpation. Ischemic injury was performed by clamping the renal artery and vein for 60 min. After removing the clamps or directly after catheterization of healthy kidneys, 10 million MSCs suspended in 25 mL DPBS were infused into the renal artery followed by a 5 mL DPBS flush both at a rate of 150 mL/h.

In both healthy and ischemic kidneys, the renal artery catheter was removed after 10 min when MSC administration was finished. Blood was collected simultaneously from the carotid artery and renal vein before, during, and after MSC infusion. Bilateral nephrectomy was completed after either 30 min or 8 h follow-up, and the pig was terminated using an IV overdose of pentobarbital (100 mg/kg) while in general anesthesia. Both kidneys were weighted, and cut

FIG. 2. Intra-arterially delivered MSCs are retained in the kidneys. **(A)** MSC per gram of renal cortical tissue of healthy and injured kidneys 30 min after infusion ($n = 3$ and $n = 4$, respectively) and of ischemic kidneys 8 h after infusion ($n = 3$). **(B)** Viability of MSC in healthy or ischemic renal cortical tissue after 30 min and in ischemic renal cortical tissue after 8 h. **(C)** Size of MSC before infusion and MSC found in the renal cortex, renal medulla, and venous outflow. **(D)** MSC per gram of renal cortex, renal medulla, and lung. MSC per milliliter of whole blood drawn from the renal vein or the carotid artery. * p -value < 0.05 , ** p -value < 0.01 .

longitudinally and horizontally through the medial line after retrieval. Kidney weight ranged from 90 to 110 g in all pigs. One half of each kidney was used to obtain all tissue material used for analysis, and the other one was embedded in PELCO[®] cryoembedding compound (Ted Pella, Inc., Redding, CA) and cryopreserved. Each experimental group consisted of three pigs.

Noninvasive MSC infusion

The data presented in Figs. 6 and 7 were obtained from a noninvasive MSC delivery method. Over a guidewire in the femoral introducer sheath, a catheter was introduced into the aorta, and contrast agent (Iomeron 350 mg/mL, total volume used 40 mL) was administered using X-ray to ensure the correct positioning of the catheter in the renal artery. Hereafter, 10 million MSCs in 25 mL DPBS were infused into the renal artery followed by a 5 mL DPBS flush both at a rate of 150 mL/h. The renal artery catheter was removed after 10 min, when MSC administration was finished.

Bilateral nephrectomy was completed after 30 min ($n = 3$) or 14 days follow-up ($n = 8$ and $n = 4$ for MSC- and HI-MSC-infused kidneys, respectively), and the pig was terminated using an IV overdose of pentobarbital (100 mg/kg) while in general anesthesia. Kidney weight ranged from 90 to 110 g in all pigs.

FIG. 3. MSCs are located mainly in renal cortex after infusion through the renal artery. **(A)** Three-dimensional volume rendering of half a kidney from the lateral and the medial side generated from brightfield data. **(B)** Detected Qdot-positive cells pseudocolored in yellow and rendered along with brightfield volume from the lateral and medial side.

FIG. 4. MSCs are found primarily inside glomeruli. Micrograph of healthy renal tissue. Arrows depict Qdot 655 red fluorescence from MSC. Pictures were obtained from healthy renal tissue 30 min after fluorescent MSC infusion. (A) Overview of renal cortical tissue overlaying renal tissue autofluorescence in *grayscale* and signal from Qdot 655 in *red*. (B) One single glomerulus occupied by several MSCs. Zoomed in image of a glomerulus full of MSCs. (C) Renal cortex with MSCs found inside glomeruli and around tubules. Zoomed in image of MSCs outside glomeruli. (D) Renal medulla with MSCs found between tubuli. Zoomed in image of MSCs around tubuli in renal medulla.

MSC detection in kidney and blood by flow cytometry

Blood samples and renal tissue were analyzed using flow cytometry. Whole blood samples drawn from the renal vein and the carotid artery were directly analyzed. From the total dissociated kidney tissue, 400 μ L were analyzed by flow cytometry. The fluorescence was measured by excitation with a 405 nm laser and detection with the 660/20 BP, 650 LP filter set in a Novocyte flow cytometer (ACEA Biosciences, Inc.). To avoid low-fluorescent cells from being measured and to speed up the measuring process, a fluo-

rescence threshold (median fluorescent intensity = 5,000) was applied. Qdot-positive cells found in the cell suspensions were identified as the infused MSC.

To confirm that the Qdot-positive cells found in dissociated renal tissue and in whole blood were indeed the infused MSCs, simultaneous expression of CD29, CD44, and CD90 and absence of CD31 and CD45 were assessed as mentioned earlier for MSC characterization. The viability of MSC was assessed using the Zombie NIR™ Fixable Viability Kit (Biolegend). From the dissociated renal tissue, 100 μ L were stained with Zombie NIR™ following the manufacturer's protocol and analyzed by flow cytometry. The total number of MSCs in kidney

FIG. 5. HI-MSCs do not adhere to plastic in vitro. (A) PKH26-labeled MSC adhered to the culture flask 1 and 6 h after seeding. (B) PKH26-labeled HI-MSC did not adhere to the culture flask 1 or 6 h after seeding. HI, heat inactivated.

tissue or blood was estimated from the number of events and the volume measured from each sample. Flow cytometry data were analyzed using NovoExpress software (ACEA Biosciences, Inc.).

Confocal microscopy of renal tissue

Kidney biopsies, containing both renal cortex and medulla, of 1 cm³ formalin-fixed and paraffin-embedded renal tissue were cut into 3 μm thick slices. Images were obtained using a Leica SP5 confocal microscope (Leica Micro-

systems, Wetzlar, Germany). Renal tissue autofluorescence was used to identify specific kidney structures such as glomeruli and tubules. Qdot 655 signal was detected by exciting the samples at a wavelength of 405 nm and measuring fluorescence emission at 655 nm. Tissue autofluorescence was measured at 420 nm to identify different renal structures. Images were analyzed using Fiji from ImageJ.

Cell localization by three-dimensional cryoimaging

Half kidneys were embedded in mounting medium for cryotomy (PELCO cryoembedding compound, Ted Pella, Inc.) and frozen in liquid nitrogen. Frozen kidneys were kept at -80°C and shipped to BioInVision (OH). At BioInVision, quantification of engrafted MSC was performed based on detection of fluorescent signal.

Statistical analysis

The Mann–Whitney test was used for comparison of mean numbers of MSCs found in renal and lung tissue and MSCs found in the blood outflow from the renal vein. The Kruskal–Wallis test was used when more than two groups were compared at the same time. Data were analyzed using GraphPad Prism version 5.00 for Windows (GraphPad Software, La Jolla, CA).

Results

MSC quantification in blood and tissue

Qdot-labeled MSCs showed a high-fluorescent signal, which allowed clear identification of the cells by flow

FIG. 6. MSC stay in the kidney through a passive mechanism. (A) MSC and HI-MSC per gram of renal cortex 30 min after infusion in a healthy kidney (*n*=3). (B) Viability of MSC and HI-MSC in renal cortical tissue 30 min after infusion in a healthy kidney (*n*=3). (C) Plastic-adherent Qdot-positive MSCs in dissociated kidney tissue after 1 day of culturing (*n*=3). (D) Arrows depict Qdot 655 red fluorescence from MSC. HI-MSCs are located mostly inside glomeruli 30 min after infusion in healthy kidneys. (E) Detected Qdot-labeled HI-MSCs are pseudocolored in yellow and rendered along with brightfield volume from both the lateral and medial sides.

FIG. 7. MSCs are cleared from the kidney within 14 days. **(A)** Relative Y-chromosome compared with total pig DNA in kidney tissue 30 min after MSC or HI-MSC infusion ($n=3$) and 14 days after infusion of MSC ($n=8$) or HI-MSC ($n=6$). **(B)** Relative amount of Y-chromosome of the plastic-adherent cell fraction of dissociated kidney tissue isolated 30 min ($n=3$) and 14 days after infusion of MSC ($n=6$) and HI-MSC ($n=4$) after 1 day of culture.

cytometry (Supplementary Fig. S1A). To demonstrate the feasibility of a flow cytometry-based detection technique of relatively low numbers of MSCs in large amounts of kidney and blood cells, Qdot-labeled MSCs were mixed with dissociated renal tissue and whole blood in vitro. Results showed that Qdot-labeled MSCs could be semiquantitatively measured in these samples (Supplementary Fig. S2B, C).

MSC detection after renal intra-arterial delivery

In total, 10 million Qdot-labeled MSCs were infused in vivo through the renal artery to healthy or ischemic kidneys, and 30 min after administration renal tissue was analyzed for the presence of Qdot-labeled MSCs. We observed that MSCs were successfully delivered to both healthy and ischemic kidneys (Fig. 2A, D and Supplementary Fig. S2B, C).

Measured MSCs were in the order of $1-4 \times 10^4$ MSCs per gram of dissociated cortical tissue. To demonstrate that MSCs were stably retained in the kidney, the follow-up time of the ischemic group was extended to 8 h. This demonstrated that the majority of MSCs remained in the kidney at least up to 8 h. The viability of MSC in the kidney tissue measured by flow cytometry ranged from 70% to 80% in all three conditions (Fig. 2B). We observed that MSCs found in the renal cortex had a bigger size than those found in the renal medulla (Fig. 2C).

Qdot-labeled MSCs were also detected in dissociated renal medulla; however, MSC numbers were 10-fold lower than those found in the renal cortex. Lung tissue contained numbers 100-fold lower compared with renal cortex, with an average of 200 MSCs per gram of tissue (Fig. 1D).

During the experiments described above, blood samples from the renal vein and carotid artery were drawn to identify the presence of MSCs passing through the kidneys. During infusion, an average of 500 MSCs per milliliter were measured leaving the kidney through the renal vein. After the infusion stopped, hardly any MSC were found leaving the kidney (Fig. 1D and Supplementary Fig. S3A). In blood samples from the carotid artery, no MSCs were detected either during or after infusion (Supplementary Fig. 3B). The size of the MSC found in the renal vein outflow was smaller than those retained in the kidney, in both cortical and medullar tissues (Fig. 2C).

Qdot-labeled MSCs identified in blood and renal tissue were phenotyped to confirm MSC characteristics. Identified

MSC expressed CD29, CD90, and CD105 and lacked the expression of CD31 and CD45 (Supplementary Fig. S4A–D).

Cortical localization of MSC after renal intra-arterial infusion was confirmed by three-dimensional cryoimaging

Three-dimensional (3D) cryoimaging was used to confirm the presence and localization of fluorescent MSCs in the kidney. Kidneys were collected 30 min after administration of 10 million Qdot-labeled MSC and cryoimaged. In Fig. 3A, a 3D volume rendering generated from brightfield data from the lateral and medial sides of the kidney are shown. Detected Qdot-positive MSCs were pseudocolored in yellow and rendered along with brightfield data. MSCs were mainly observed in renal cortical tissue (Fig. 3B), supporting the data obtained by flow cytometry.

MSCs are located mainly in glomerular structures

Confocal microscopy demonstrated that MSCs were localized mostly to glomerular structures in the renal cortex. There was no clear difference regarding the location of MSC observed in healthy and ischemic kidneys. Pictures shown in Fig. 4 were taken from healthy kidney tissue. Frequently, several MSCs were observed in single glomeruli (Fig. 4A–C). The frequency of MSC outside the glomerular structures was much lower. However, MSC could be identified around tubules in both the renal cortex and medulla (Fig. 4C, D, respectively).

MSC stay in the kidney through a passive mechanism

To study the mechanism responsible for MSC retention in kidneys, we examined the retention of inactivated MSCs in the kidney. HI-MSCs were generated by heating MSC to 50°C for 30 min, which made them metabolically inactive and therefore they lost their ability to adhere (Fig. 5).

Regular MSC or HI-MSC were infused in-vivo through the renal artery to healthy kidneys and MSC presence was assessed 30 min after administration by flow cytometry. HI-MSC were retained in similar numbers in the kidney as regular MSC (Fig. 6A).

Viability analysis of retained MSC confirmed that regular MSC infused to the kidney remained alive in the renal cortex, whereas infused HI-MSC were indeed non-viable (Fig. 6B). Dissociated renal tissue containing MSC was seeded in a culture dish to examine the adherent capacity of MSC in the tissue. Analysis of the adherent fraction of dissociated renal tissue demonstrated the presence of plastic-adherent Qdot-positive MSC, while only background fluorescence was detected in the HI-MSC group (Fig. 6C). Confocal microscopy and 3D cryoimaging of HI-MSC infused kidneys confirmed that HI-MSC were located in the same renal structures as regular MSC (Fig. 6D, E, respectively).

The majority of MSC are cleared from the kidney within 2 weeks

Male MSC were administered to female pigs which allowed male MSC tracing by a qPCR of a MSR located on the pig Y-chromosome. First, renal tissue was analyzed for the presence of Y-chromosome in kidneys harvested 30 min after infusion of 10 million MSC or HI-MSC. This demonstrated that both MSC- and HI-MSC-infused kidneys contained high amounts of Y-chromosome 30 min after MSC delivery (Fig. 7A).

The same experiment was repeated with 14 days follow-up. This showed that Y-chromosome could be detected 14 days after MSC infusion, whereas no such signal was detected in HI-MSC-infused kidneys. Although Y-chromosome DNA was detected after 14 days, the average relative amount at day 14 was ~1% of the amount measured 30 min after infusion. Moreover, three of eight analyzed kidneys showed Y-chromosome DNA signal just above threshold.

Viability of the detected MSC was demonstrated as previously described by analyzing the plastic-adherent fraction of the dissociated renal tissue. This showed that dissociated renal tissue isolated 14 days after MSC delivery contained living, plastic-adherent male MSC, whereas no male MSC could be found in the plastic-adherent fraction of HI-MSC infused kidneys (Fig. 7B).

Discussion

In this study, we have tested the efficiency and tissue distribution of in vivo MSC infusion through the renal artery in a porcine ischemia-reperfusion injury model. We showed that targeted MSC delivery through the renal artery is a feasible route to deliver MSCs to the kidney. Upon infusion, MSCs are distributed throughout the kidney, located mostly in renal cortex, and particularly inside glomeruli. MSCs are retained in renal tissue presumably through a passive mechanism, and after infusion they survive for ~8 h. The majority of MSCs were cleared from the kidneys within 2 weeks.

We show that renal intra-arterial-targeted infusion of MSCs minimizes off-target delivery as only small numbers of MSCs leave the kidney during infusion. Previous studies in animal models have simply associated the observed effects with the number of infused, but not delivered, MSCs to the injured kidney [25,32,33]. In our study, we actually quantify the number of MSCs delivered to the target tissue, which enables us to correlate observed effects with the MSC dose in future studies.

To do this, we used a semiquantitative flow cytometric method, which can be used to quantify MSC delivered to the

kidney through renal intra-arterial infusion. Our approach using prelabeled MSC in combination with flow cytometric analysis of dissociated kidney tissue allowed us to have a good estimate of the absolute amount of MSCs that were retained in the kidney. Infusion of 10 million MSCs to the kidney resulted in numbers in the order of $1-4 \times 10^4$ MSCs per gram of renal tissue delivered throughout the kidney, although the distribution was not completely homogeneous. Extrapolation of measured concentrations of MSCs using total kidney weight indicates that several million MSCs were delivered per kidney. This number points out that a significant amount of MSCs is not found back in the kidney.

However, it should be noted that the measured numbers are a minimum value, as part of the MSC might be lost during the tissue dissociation and analysis process. It is still unknown whether this number of MSCs is biologically relevant or therapeutically effective on the kidney. Therefore, our work paves the way for new studies to address this issue.

MSCs were retained mostly in glomeruli as demonstrated in other studies [24,25,32,33]. MSCs are relatively large, so they might simply get entrapped in the microcapillaries of glomerular structures in a similar manner to MSCs that are entrapped in the lung's capillary network after IV infusion [17]. However, the size of MSC used in our experiments averaged 16 μ m, which is similar to some white blood cells, which are able to pass through the microcapillaries of glomeruli. Red and white blood cells can deform by altering their cytoskeletal structure to be able to flow through microcapillaries [34–36]. However, MSCs are originally tissue-resident cells, which might be a reason not to have the same shape deformation capacities [37,38].

Moreover, HI-MSCs were retained in the same structures. These cells are not metabolically active and therefore unable to deform, which supports our hypothesis of a passive retention mechanism. We have shown that only bigger MSCs were found in the renal cortex, while smaller MSCs could pass through the glomerular microcapillaries and end up in the renal medulla or even leave the kidney. In a rat model, infused MSC stayed in the kidney, whereas other infused cell type, of the same size, failed to stay in renal tissue [24]. This fact suggests that MSCs are specifically retained by the kidney itself.

In the case that MSCs get stuck in the glomerular microcapillaries network, there might be some safety concerns as renal blood flow or function might be compromised. It has been reported in a rat model that after infusion of very high numbers of MSCs, parenchymal perfusion decreased, and it was restored to normality after 24 h [32]. Furthermore, several murine preclinical studies showed improved function of injured kidneys after delivery of MSC through the renal artery with no adverse effects [23,24,39]. Besides, a human clinical trial has not reported serious adverse effects upon renal intra-arterial infusion of MSCs and even showed, to some extent, improved kidney function [29].

MSCs have been shown to be short lived after IV infusion [17,18,40]. However, renal intra-arterial infusion of MSC seems to ensure longer survival of MSCs after infusion. In our study, MSC viability in the kidney 8 h after infusion was ~70%–80%. However, after 14 days, most MSCs were cleared from the kidney. Nevertheless, large animal studies have shown the presence of MSCs up to 5 weeks after renal intra-arterial infusion [25], in contrast to

our findings. In these large animal models, mostly autologous MSCs are used [25–27,33], whereas rodent renal intra-arterial MSC infusion models usually employ allogeneic MSCs [21,23,24]. In both cases, similar survival of infused MSC was observed, which suggests that the origin of MSC does not affect survival after delivery.

From a logistic and translational point of view, the use of allogeneic MSC is more appealing as large numbers of therapeutic MSCs should be readily available for treatment. Our results confirm that infusion of allogeneic MSC is feasible in large animal models and enables survival of MSC in renal tissue.

The mechanism behind MSC retention after renal intra-arterial infusion is, so far, poorly understood. Although we have shown that retention of MSC in the kidney is independent of the metabolic status of the infused MSC, they could be actively attached by the glomerular endothelium. It has been described that MSCs can physically interact with endothelial cells through adhesion molecules present in their membrane, such as very late antigen 4 [41,42]. As HI-MSCs maintain the proteins expressed on their membrane, they may still be able to interact with the endothelium through this mechanism. The elucidation of the mechanisms behind the effects of MSC is essential to further develop MSC therapies.

However, conflicting data found in the literature defend both the paracrine secretion of cytokines [43,44] and the physical interaction with other cells [18,30] as the main mechanism of MSC action. This makes it difficult to draw a conclusion and therefore, additional experimentation is indeed needed.

Summarizing, renal intra-arterially infused MSCs are delivered particularly to the glomeruli and survive for ~8 h after infusion. Their presence can potentially allow them to interact with injured tissue and elicit a regenerative response. To completely understand the potential of MSC therapy in kidneys, further studies are now starting to decipher the specific mechanisms of action of MSC after renal intra-arterial delivery, which will contribute to an improved MSC therapy for treatment of kidney injury.

Acknowledgments

This project is funded by the Lundbeck Foundation under grant application no. R198-2015-184 and Fabrikant Vilhelm Pedersen og Hustrus Legat under grant application no. 22720 2016.

Author Disclosure Statement

No competing financial interests exist.

Supplementary Material

Supplementary Figure S1
Supplementary Figure S2
Supplementary Figure S3
Supplementary Figure S4

References

- Morigi M, C Rota and G Remuzzi. (2016). Mesenchymal stem cells in kidney repair. *Methods Mol Biol* 1416: 89–107.
- Peired AJ, A Sisti and P Romagnani. (2016). Mesenchymal stem cell-based therapy for kidney disease: a review of clinical evidence. *Stem Cells Int* 2016:4798639.
- Baraniak PR and TC McDevitt. (2010). Stem cell paracrine actions and tissue regeneration. *Regen Med* 5:121–143.
- Morishita R, S Nakamura, Y Nakamura, M Aoki, A Moriguchi, I Kida, Y Yo, K Matsumoto, T Nakamura, J Higaki and T Ogihara. (1997). Potential role of an endothelium-specific growth factor, hepatocyte growth factor, on endothelial damage in diabetes. *Diabetes* 46:138–142.
- Nakano N, R Morishita, A Moriguchi, Y Nakamura, SI Hayashi, M Aoki, I Kida, K Matsumoto, T Nakamura, J Higaki and T Ogihara. (1998). Negative regulation of local hepatocyte growth factor expression by angiotensin II and transforming growth factor-beta in blood vessels: potential role of HGF in cardiovascular disease. *Hypertension* 32: 444–451.
- Yang Y, QH Chen, AR Liu, XP Xu, JB Han and HB Qiu. (2015). Synergism of MSC-secreted HGF and VEGF in stabilising endothelial barrier function upon lipopolysaccharide stimulation via the Rac1 pathway. *Stem Cell Res Ther* 6:250.
- Burlacu A, G Grigorescu, AM Rosca, MB Preda and M Simionescu. (2013). Factors secreted by mesenchymal stem cells and endothelial progenitor cells have complementary effects on angiogenesis in vitro. *Stem Cells Dev* 22:643–653.
- Qi Y, D Jiang, A Sindrilaru, A Stegemann, S Schatz, N Treiber, M Rojewski, H Schrezenmeier, S Vander Beken, M Wlaschek, et al. (2014). TSG-6 released from intradermally injected mesenchymal stem cells accelerates wound healing and reduces tissue fibrosis in murine full-thickness skin wounds. *J Invest Dermatol* 134:526–537.
- Geng Y, L Zhang, B Fu, J Zhang, Q Hong, J Hu, D Li, C Luo, S Cui, F Zhu and X Chen. (2014). Mesenchymal stem cells ameliorate rhabdomyolysis-induced acute kidney injury via the activation of M2 macrophages. *Stem Cell Res Ther* 5:80.
- Bouffi C, C Bony, G Courties, C Jorgensen and D Noel. (2010). IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. *PLoS One* 5:e14247.
- Iwai S, I Sakonju, S Okano, T Teratani, N Kasahara, S Yokote, T Yokoo and E Kobayash. (2014). Impact of ex vivo administration of mesenchymal stem cells on the function of kidney grafts from cardiac death donors in rat. *Transplant Proc* 46:1578–1584.
- Morigi M, B Imberti, C Zoja, D Corna, S Tomasoni, M Abbate, D Rottoli, S Angioletti, A Benigni, et al. (2004). Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. *J Am Soc Nephrol* 15:1794–1804.
- Ebrahimi B, A Eirin, Z Li, XY Zhu, X Zhang, A Lerman, SC Textor and LO Lerman. (2013). Mesenchymal stem cells improve medullary inflammation and fibrosis after revascularization of swine atherosclerotic renal artery stenosis. *PLoS One* 8:e67474.
- Baulier E, F Favreau, A Le Corf, C Jayle, F Schneider, JM Goujon, O Feraud, A Bennaceur-Griscelli, T Hauet and AG Turhan. (2014). Amniotic fluid-derived mesenchymal stem cells prevent fibrosis and preserve renal function in a pre-clinical porcine model of kidney transplantation. *Stem Cells Transl Med* 3:809–820.

15. Reinders MEJ, C van Kooten, TJ Rabelink and JW de Fijter. (2018). Mesenchymal stromal cell therapy for solid organ transplantation. *Transplantation* 102:35–43.
16. Gao J, JE Dennis, RF Muzic, M Lundberg and AI Caplan. (2001). The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. *Cells Tissues Organs* 169:12–20.
17. Eggenhofer E, V Benseler, A Kroemer, FC Popp, EK Geissler, HJ Schlitt, CC Baan, MH Dahlke and MJ Hoogduijn. (2012). Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. *Front Immunol* 3:297.
18. de Witte SFH, F Luk, JM Sierra Parraga, M Garghesha, A Merino, SS Korevaar, AS Shankar, L O'Flynn, SJ Elliman, et al. (2018). Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells. *Stem Cells* 36:602–615.
19. Fischer UM, MT Harting, F Jimenez, WO Monzon-Posadas, H Xue, SI Savitz, GA Laine and CS Cox, Jr. (2009). Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. *Stem Cells Dev* 18:683–692.
20. Sun JH, GJ Teng, ZL Ma and SH Ju. (2008). In vivo monitoring of magnetically labeled mesenchymal stem cells administered intravascularly in rat acute renal failure. *Swiss Med Wkly* 138:404–412.
21. Togel F, Y Yang, P Zhang, Z Hu and C Westenfelder. (2008). Bioluminescence imaging to monitor the in vivo distribution of administered mesenchymal stem cells in acute kidney injury. *Am J Physiol Renal Physiol* 295:F315–F321.
22. Zonta S, M De Martino, G Bedino, G Piotti, T Rampino, M Gregorini, F Frassoni, A Dal Canton, P Dionigi and M Alessiani. (2010). Which is the most suitable and effective route of administration for mesenchymal stem cell-based immunomodulation therapy in experimental kidney transplantation: endovenous or arterial? *Transplant Proc* 42:1336–1340.
23. Franchi F, KM Peterson, R Xu, B Miller, PJ Psaltis, PC Harris, LO Lerman and M Rodriguez-Porcel. (2015). Mesenchymal stromal cells improve renovascular function in polycystic kidney disease. *Cell Transplant* 24:1687–1698.
24. Kunter U, S Rong, Z Djuric, P Boor, G Muller-Newen, D Yu and J Floege. (2006). Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. *J Am Soc Nephrol* 17:2202–2212.
25. Behr L, M Hekmati, G Fromont, N Borenstein, LH Noel, M Lelievre-Pegorier and K Laborde. (2007). Intra renal arterial injection of autologous mesenchymal stem cells in an ovine model in the postischemic kidney. *Nephron Physiol* 107:65–76.
26. Eirin A, XY Zhu, JD Krier, H Tang, KL Jordan, JP Grande, A Lerman, SC Textor and LO Lerman. (2012). Adipose tissue-derived mesenchymal stem cells improve revascularization outcomes to restore renal function in swine atherosclerotic renal artery stenosis. *Stem Cells* 30:1030–1041.
27. Moghadasali R, M Azarnia, M Hajinasrollah, H Arghani, SM Nassiri, M Molazem, A Vosough, S Mohitmafi, M Najarasl, et al. (2014). Intra-renal arterial injection of autologous bone marrow mesenchymal stromal cells ameliorates cisplatin-induced acute kidney injury in a rhesus *Macaque mulatta* monkey model. *Cytotherapy* 16:734–749.
28. Lee KW, TM Kim, KS Kim, S Lee, J Cho, JB Park, GY Kwon and SJ Kim. (2018). Renal ischemia-reperfusion injury in a diabetic monkey model and therapeutic testing of human bone marrow-derived mesenchymal stem cells. *J Diabetes Res* 2018:5182606.
29. Saad A, AB Dietz, SMS Herrmann, LJ Hickson, JF Glockner, MA McKusick, S Misra, H Bjarnason, AS Armstrong, et al. (2017). Autologous mesenchymal stem cells increase cortical perfusion in renovascular disease. *J Am Soc Nephrol* 28:2777–2785.
30. Luk F, SF de Witte, SS Korevaar, M Roemeling-van Rhijn, M Franquesa, T Strini, S van den Engel, M Garghesha, D Roy, et al. (2016). Inactivated mesenchymal stem cells maintain immunomodulatory capacity. *Stem Cells Dev* 25:1342–1354.
31. Gruessner RW, BK Levay-Young, RE Nakhleh, JD Shearer, M Dunning, CM Nelson and AC Gruessner. (2004). Portal donor-specific blood transfusion and mycophenolate mofetil allow steroid avoidance and tacrolimus dose reduction with sustained levels of chimerism in a pig model of intestinal transplantation. *Transplantation* 77:1500–1506.
32. Cai J, X Yu, R Xu, Y Fang, X Qian, S Liu, J Teng and X Ding. (2014). Maximum efficacy of mesenchymal stem cells in rat model of renal ischemia-reperfusion injury: renal artery administration with optimal numbers. *PLoS One* 9:e92347.
33. Behr L, M Hekmati, A Lucchini, K Houcinet, AM Faussat, N Borenstein, LH Noel, M Lelievre-Pegorier and K Laborde. (2009). Evaluation of the effect of autologous mesenchymal stem cell injection in a large-animal model of bilateral kidney ischaemia reperfusion injury. *Cell Prolif* 42:284–297.
34. Redenbach DM, D English and JC Hogg. (1997). The nature of leukocyte shape changes in the pulmonary capillaries. *Am J Physiol* 273:L733–L740.
35. Li J, G Lykotrafitis, M Dao and S Suresh. (2007). Cytoskeletal dynamics of human erythrocyte. *Proc Natl Acad Sci U S A* 104:4937–4942.
36. Ekpenyong AE, N Toepfner, C Fiddler, M Herbig, W Li, G Cojoc, C Summers, J Guck and ER Chilvers. (2017). Mechanical deformation induces depolarization of neutrophils. *Sci Adv* 3:e1602536.
37. Fraser JK, I Wulur, Z Alfonso and MH Hedrick. (2006). Fat tissue: an underappreciated source of stem cells for biotechnology. *Trends Biotechnol* 24:150–154.
38. Beltrami AP, L Barlucchi, D Torella, M Baker, F Limana, S Chimenti, H Kasahara, M Rota, E Musso, et al. (2003). Adult cardiac stem cells are multipotent and support myocardial regeneration. *Cell* 114:763–776.
39. Jang MJ, D You, JY Park, K Kim, J Aum, C Lee, G Song, HC Shin, N Suh, YM Kim and CS Kim. (2018). Hypoxic preconditioned mesenchymal stromal cell therapy in a rat model of renal ischemia-reperfusion injury: development of optimal protocol to potentiate therapeutic efficacy. *Int J Stem Cells* 11:157–167.
40. Eggenhofer E, F Luk, MH Dahlke and MJ Hoogduijn. (2014). The life and fate of mesenchymal stem cells. *Front Immunol* 5:148.
41. Rusten B, S Gottig, RJ Ludwig, R Bistrrian, S Muller, E Seifried, J Gille and R Henschler. (2006). Mesenchymal

- stem cells display coordinated rolling and adhesion behavior on endothelial cells. *Blood* 108:3938–3944.
42. Segers VF, I Van Riet, LJ Andries, K Lemmens, MJ Demolder, AJ De Becker, MM Kockx and GW De Keulenaer. (2006). Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms. *Am J Physiol Heart Circ Physiol* 290: H1370–H1377.
43. Brasile L, N Henry, G Orlando and B Stubenitsky. (2019). Potentiating renal regeneration using mesenchymal stem cells. *Transplantation* 103:307–313.
44. Kim HK, SG Lee, SW Lee, BJ Oh, JH Kim, JA Kim, G Lee, JD Jang and YA Joe. (2019). A subset of paracrine factors as efficient biomarkers for predicting vascular regenerative efficacy of mesenchymal stromal/stem cells. *Stem Cells* 37:77–88.

Address correspondence to:
Jesus M. Sierra-Parraga
Nephrology and Transplantation
Internal Medicine Department
University Medical Center Rotterdam
Erasmus MC
Postbus 2040
Rotterdam, CA 3000
The Netherlands

E-mail: j.sierraparraga@erasmusmc.nl

Received for publication May 15, 2019

Accepted after revision July 5, 2019

Prepublished on Liebert Instant Online July 6, 2019